Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in MobiHealthNews, in “A Look Ahead at Digital Health and Health Policy Under President Trump.”
Following is an excerpt:
When we looked at the future of the FDA under Trump in November, FDA expert Bradley Merrill Thompson, a partner at Epstein Becker Green, told us digital health folks had room for optimism about Trump’s approach to the agency.
“From everything I’ve heard, Trump is very supportive of technology development, and very concerned about regulatory red tape. So I think we can feel confident that Trump will certainly not increase the regulation of digital health,” he told us at the time. “The bottom line is, while the two men seem to disagree on just about everything, it would appear that the two men might actually agree on the need to support the development of digital health, and we can expect a continuation of those policies under the Trump administration.”